Telix Pharmaceuticals Ltd
Company Profile
Business description
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Contact
55 Flemington Road
Suite 401, North Melbourne
MelbourneVIC3051
AUST: +61 449148448
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
234
Telix Pharmaceuticals Ltd News & Analysis
stocks
What we think of the 3 big winners of the ASX 100
stocks
Ask the analyst: Are Telix's growth prospects priced in?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,558.60 | 0.00 | 0.00% |
| CAC 40 | 7,384.62 | 18.92 | 0.26% |
| DAX 40 | 20,242.57 | 3.80 | -0.02% |
| Dow JONES (US) | 43,613.66 | 163.76 | 0.38% |
| FTSE 100 | 8,199.11 | 3.91 | 0.05% |
| HKSE | 19,864.55 | 164.07 | 0.83% |
| NASDAQ | 20,149.00 | 39.94 | 0.20% |
| Nikkei 225 | 39,081.71 | 282.97 | -0.72% |
| NZX 50 Index | 12,865.55 | 48.75 | -0.38% |
| S&P 500 | 6,061.89 | 11.28 | 0.19% |
| S&P/ASX 200 | 8,309.40 | 4.60 | -0.06% |
| SSE Composite Index | 3,382.21 | 20.72 | 0.62% |